Wuxi Biologics (Cayman) (2269) Price & Analysis

Compare

53 Followers

2269 Stock Chart & Stats

HK$34.16

HK$0.44(2.67%)

At close: Jan 09 4:00 PM EST

HK$34.16

HK$0.44(2.67%)

Day’s Range― - ―

52-Week RangeHK$15.62 - HK$42.60

Previous CloseN/A

Volume35.71M

Average Volume (3M)32.67M

Market Cap

HK$141.02B

Enterprise ValueHK$103.71B

Total Cash (Recent Filing)HK$12.54B

Total Debt (Recent Filing)HK$5.11B

Price to Earnings (P/E)30.6

Beta1.70

Next Earnings

Mar 31, 2026

EPS Estimate

0.62

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.61

Shares Outstanding4,128,114,000

10 Day Avg. Volume33,789,006

30 Day Avg. Volume32,668,415

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.61

Price to Sales (P/S)3.60

P/FCF Ratio52.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$42.17

Price Target Upside23.46% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Earnings1H25 net profit grew by 56% year over year to RMB2.34bn, beating consensus expectations.

Revenue GrowthWuXi Biologics raised its full-year revenue growth guidance, with the fastest-growing segment being its bioconjugates subsidiary, WuXi XDC.

Strategic AcquisitionsAcquisition of 86 new integrated projects, with over half sourced from US biotech companies, includes projects with blockbuster potential and first-in-class drug candidates.

Bears Say

Regulatory RisksThe proposed US Biosecure Act poses regulatory headwinds.

Sales RiskIf WuXi Bio is targeted by the Biosecure Act, it would be banned after five years, which may put its sales from the US at risk.

Wuxi Biologics (Cayman) News

Wuxi Biologics Proposes Revised Cap and Renewal of Service Agreement Amid Growing Demand

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an update. Wuxi Biologics announced a proposal to revise the...

4M ago

Wuxi Biologics Reports Strong Growth in H1 2025

Wuxi Biologics (Cayman) ( ($WXIBF) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

WuXi Biologics to Present 2025 Interim Results in Upcoming Conference Calls

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an announcement. WuXi Biologics (Cayman) Inc. has announced it will...

4M ago

Wuxi Biologics Reports Strong Growth in H1 2025

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an announcement. Wuxi Biologics reported strong financial performance for the...

4M ago

WuXi Biologics Reports Robust Financial Growth for H1 2025

An update from Wuxi Biologics (Cayman) ( ($HK:2269) ) is now available. WuXi Biologics has announced a significant...

5M ago

WuXi Biologics Schedules Board Meeting to Review Interim Results

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an announcement. WuXi Biologics (Cayman) Inc. has announced a board...

5M ago

WuXi Biologics Announces Share Placement by Substantial Shareholder

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an announcement. WuXi Biologics (Cayman) Inc. announced that its substantial...

6M ago

WuXi Biologics Announces AGM Results and Board Changes

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an announcement. WuXi Biologics (Cayman) Inc. announced the results of...

7M ago

WuXi Biologics Announces Board Composition and Roles

The latest announcement is out from Wuxi Biologics (Cayman) ( ($HK:2269) ). WuXi Biologics (Cayman) Inc. has announced...

7M ago

Wuxi Biologics Grants Restricted Shares to Motivate Employee

An announcement from Wuxi Biologics (Cayman) ( ($HK:2269) ) is now available. Wuxi Biologics has announced the grant...

7M ago

WuXi Biologics downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50....

2y ago

GSK, WuXi Biologics enter into license agreement on TCE antibodies

WuXi Biologics (WXIBF) announced a license agreement with GSK plc (GSK) under which GSK will have exclusive licenses...

3y ago

GSK

2269 FAQ

What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?

Wuxi Biologics (Cayman) Inc. lowest stock price was HK$15.62 and its highest was HK$42.60 in the past 12 months.

What is Wuxi Biologics (Cayman) Inc.’s market cap?

Wuxi Biologics (Cayman) Inc.’s market cap is HK$141.02B.

When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?

Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Mar 31, 2026 which is in 97 days.

How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?

Wuxi Biologics (Cayman) Inc. released its earnings results on Aug 19, 2025. The company reported HK$0.607 earnings per share for the quarter, beating the consensus estimate of HK$0.497 by HK$0.11.

Is Wuxi Biologics (Cayman) Inc. overvalued?

According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wuxi Biologics (Cayman) Inc. pay dividends?

Wuxi Biologics (Cayman) Inc. does not currently pay dividends.

What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?

Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.62.

How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?

Wuxi Biologics (Cayman) Inc. has 4,128,114,000 shares outstanding.

What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?

Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.607 in its last earnings report, beating expectations of HK$0.497. Following the earnings report the stock price went down -3.935%.

Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?

Currently, no hedge funds are holding shares in HK:2269

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Wuxi Biologics (Cayman) Stock Smart Score

Outperform

Analyst Consensus

Strong Buy

Average Price Target:
HK$42.17 (23.46% Upside)

Technicals

Fundamentals

Return on Equity

9.79%

Trailing 12-Months

Asset Growth

9.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Wuxi Biologics (Cayman) Inc.

Wuxi Biologics (Cayman) Inc. is a leading global open-access biologics technology platform, providing comprehensive services for the development and manufacture of biologics, including monoclonal antibodies, vaccines, and other biologic therapeutics. The company operates in the biopharmaceutical sector, catering to a wide range of clients from biotechnology startups to large pharmaceutical companies. Wuxi Biologics specializes in offering integrated services that encompass the entire drug development lifecycle, from discovery and development to manufacturing and commercialization.

Wuxi Biologics (Cayman) (2269) Earnings & Revenues

Historic Earnings Reports

2269 Company Deck

2269 Earnings Call

Q2 2025

0:00 / 0:00

2269 Stock 12 Month Forecast

Average Price Target

HK$42.17

▲(23.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","50":"HK$50","19.25":"HK$19.25","29.5":"HK$29.5","39.75":"HK$39.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49.99805465903,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.174393428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$42.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.4986966215501,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$33.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,19.25,29.5,39.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,37.261388819925386,38.32277763985077,39.384166459776154,40.44555527970154,41.50694409962692,42.568332919552304,43.62972173947769,44.69111055940307,45.752499379328455,46.81388819925384,47.87527701917923,48.93666583910461,{"y":49.99805465903,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,36.65956872523077,37.119137450461544,37.57870617569231,38.03827490092308,38.49784362615385,38.95741235138462,39.416981076615386,39.87654980184615,40.33611852707693,40.795687252307694,41.25525597753846,41.714824702769235,{"y":42.174393428,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.2,35.99220743242693,35.784414864853865,35.57662229728079,35.36882972970773,35.161037162134654,34.95324459456159,34.74545202698852,34.53765945941545,34.32986689184238,34.12207432426931,33.91428175669624,33.706489189123175,{"y":33.4986966215501,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >